JP2004529874A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004529874A5 JP2004529874A5 JP2002563877A JP2002563877A JP2004529874A5 JP 2004529874 A5 JP2004529874 A5 JP 2004529874A5 JP 2002563877 A JP2002563877 A JP 2002563877A JP 2002563877 A JP2002563877 A JP 2002563877A JP 2004529874 A5 JP2004529874 A5 JP 2004529874A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- hydrogen bond
- hydrophobic group
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims 41
- 229910052739 hydrogen Inorganic materials 0.000 claims 37
- 239000001257 hydrogen Substances 0.000 claims 37
- 239000000370 acceptor Substances 0.000 claims 33
- 125000001165 hydrophobic group Chemical group 0.000 claims 33
- 125000004429 atom Chemical group 0.000 claims 23
- 102100027995 Collagenase 3 Human genes 0.000 claims 16
- 108050005238 Collagenase 3 Proteins 0.000 claims 16
- 125000006413 ring segment Chemical group 0.000 claims 16
- 239000003446 ligand Substances 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 125000005647 linker group Chemical group 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 230000007850 degeneration Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 208000028169 periodontal disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 230000008856 allosteric binding Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26882101P | 2001-02-14 | 2001-02-14 | |
| PCT/IB2002/000447 WO2002064080A2 (en) | 2001-02-14 | 2002-02-13 | Matrix metalloproteinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004529874A JP2004529874A (ja) | 2004-09-30 |
| JP2004529874A5 true JP2004529874A5 (https=) | 2005-07-21 |
Family
ID=23024626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002563877A Abandoned JP2004529874A (ja) | 2001-02-14 | 2002-02-13 | マトリックスメタロプロテイナーゼ阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20030078276A1 (https=) |
| EP (1) | EP1361873A4 (https=) |
| JP (1) | JP2004529874A (https=) |
| AR (1) | AR033859A1 (https=) |
| AU (1) | AU2002228302A1 (https=) |
| BR (1) | BR0207864A (https=) |
| CA (1) | CA2437643A1 (https=) |
| HN (1) | HN2002000037A (https=) |
| MX (1) | MXPA03007250A (https=) |
| PA (1) | PA8539301A1 (https=) |
| PE (1) | PE20020873A1 (https=) |
| PY (1) | PY0202788A (https=) |
| SV (1) | SV2002000874A (https=) |
| UY (1) | UY27174A1 (https=) |
| WO (1) | WO2002064080A2 (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8539501A1 (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
| WO2002064571A1 (en) | 2001-02-14 | 2002-08-22 | Warner-Lambert Company Llc | Pyrimidine matrix metalloproteinase inhibitors |
| DOP2002000332A (es) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
| PA8539401A1 (es) * | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
| BR0207865A (pt) | 2001-02-14 | 2004-03-23 | Warner Lambert Co | Benzotiadiazinas inibidores de metaloproteinases de matriz |
| DOP2002000334A (es) * | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz |
| US20040006205A1 (en) * | 2001-04-03 | 2004-01-08 | Li Li | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| BR0213233A (pt) | 2001-10-12 | 2005-01-04 | Warner Lambert Co | Alcinos inibidores de metaloproteinase de matriz |
| SV2003001289A (es) * | 2001-10-12 | 2003-06-24 | Warner Lambert Co | Compuestos pirimidina de anillo fusionado alquinilado |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| AU2002249275A1 (en) * | 2002-03-08 | 2003-09-22 | Warner-Lambert Company Llc | Oxo azabicyclic compounds |
| US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
| AU2002331362A1 (en) * | 2002-07-12 | 2004-02-02 | Warner-Lambert Company Llc | New alkynylated quinazolin compounds as mmp-13 inhibitors |
| MXPA05000729A (es) * | 2002-07-17 | 2005-04-08 | Warner Lambert Co | Combinacion de un inhibidor alosterico de metaloproteinasa-13 de matriz con celecoxib o valdecoxib. |
| BR0312736A (pt) * | 2002-07-17 | 2005-04-26 | Warner Lambert Co | Associação de um inibidor carboxìlico alostérico da metaloproteinase-13 de matriz com celecoxib ou valdecoxib |
| WO2004006914A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| BR0312943A (pt) * | 2002-07-17 | 2005-07-12 | Warner Lambert Co | Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib |
| AU2003281168A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| PA8578101A1 (es) * | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
| JP2005539020A (ja) | 2002-08-13 | 2005-12-22 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | マトリクスメタロプロテイナーゼ阻害物質としてのクロモン誘導体 |
| AU2003249535A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
| EP1539709A1 (en) * | 2002-08-13 | 2005-06-15 | Warner-Lambert Company LLC | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| WO2004014892A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Monocyclic derivatives as matrix metalloproteinase inhibitors |
| JP2006500350A (ja) * | 2002-08-13 | 2006-01-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテイナーゼ阻害剤としてのイソキノリン誘導体 |
| AU2003250475A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
| AU2003250482A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
| MXPA05001783A (es) * | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de pirimidina-2,4-diona como inhibidores de las metaloproteinasas de matriz. |
| WO2004014909A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| WO2004014375A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| AU2003250470A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| AU2003249539A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
| WO2004014378A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| AU2003249477A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
| WO2004014916A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| US7166609B2 (en) | 2002-11-02 | 2007-01-23 | Sanofi-Aventis Deutschland Gmbh | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases |
| US20040142950A1 (en) * | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
| WO2005002585A1 (en) * | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
| CA2534352A1 (en) | 2003-08-08 | 2005-02-17 | Arriva Pharmaceuticals, Inc. | Methods of protein production in yeast |
| WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
| EP1657238A4 (en) * | 2003-08-22 | 2008-12-03 | Takeda Pharmaceutical | CONDENSATE PYRIMIDINE DERIVATIVE AND ITS USE |
| JP2007511539A (ja) * | 2003-11-14 | 2007-05-10 | バクスター・インターナショナル・インコーポレイテッド | α１−抗トリプシン組成物およびこのような組成物を用いた処置方法 |
| US20060247231A1 (en) * | 2003-12-18 | 2006-11-02 | Warner-Lambert Company Llc | Amide and ester matrix metalloproteinase inhibitors |
| CA2559062A1 (en) * | 2004-03-09 | 2005-09-22 | Arriva Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor |
| US20070105768A1 (en) * | 2004-11-10 | 2007-05-10 | Rajiv Nayar | Dry recombinant human alpha 1-antitrypsin formulation |
| EP1820795A4 (en) | 2004-12-07 | 2010-10-20 | Toyama Chemical Co Ltd | NEW ANTHRANILIC ACID DERIVATIVE OR SALT FROM IT |
| ES2395952T3 (es) * | 2005-03-16 | 2013-02-18 | Toyama Chemical Co., Ltd. | Nuevo derivado del ácido antranílico o una sal del mismo |
| WO2006135080A1 (ja) * | 2005-06-14 | 2006-12-21 | Aska Pharmaceutical Co., Ltd. | チエノピリミジン誘導体 |
| EP1953148B1 (en) * | 2005-10-28 | 2012-02-29 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compound and use thereof |
| WO2008138126A1 (en) * | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
| WO2009086044A1 (en) * | 2007-12-19 | 2009-07-09 | Smith Kline Beecham Corporation | Prolyl hydroxylase inhibitors |
| CA2726164A1 (en) | 2008-05-27 | 2009-12-23 | The Board Of Regents Of The University Of Texas System | Wnt protein signalling inhibitors |
| JP5657201B2 (ja) * | 2008-09-30 | 2015-01-21 | サンメディカル株式会社 | 酵素阻害作用または酵素阻害作用と抗菌作用とを有する歯科用組成物 |
| CN102627657B (zh) * | 2012-03-09 | 2015-01-07 | 苏州施亚生物科技有限公司 | 3-(4-甲氧基-苄基)-1h-嘧啶-2,4-二酮衍生物的合成方法 |
| CN103012189A (zh) * | 2012-12-20 | 2013-04-03 | 天津理工大学 | 具有抗血小板聚集作用的酰胺类化合物及其制备和应用 |
| CN105793267B (zh) * | 2013-10-07 | 2018-02-06 | 拜耳制药股份公司 | 环状噻吩并尿嘧啶甲酰胺类及其用途 |
| RU2685417C1 (ru) * | 2015-05-20 | 2019-04-18 | Гуандун Рейновент Биотек Ко., Лтд. | Гидроксипуриновые соединения и их применение |
| CN107614501B (zh) | 2015-05-20 | 2020-01-14 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
| CN109593066B (zh) * | 2018-12-21 | 2020-06-19 | 上海交通大学 | 一种用于治疗肠道细菌感染的叶酸拮抗剂及其制备与应用 |
| US11919895B2 (en) * | 2019-10-25 | 2024-03-05 | Saint Louis University | GPR183 antagonists for the treatment of pain |
| CN115197225B (zh) * | 2021-09-03 | 2023-04-11 | 贵州大学 | 一种五元杂环并喹唑啉酮类化合物及其制备方法 |
| CN113773277B (zh) * | 2021-09-18 | 2023-12-05 | 兰州大学 | 一种4h-1,2,4-苯并噻二嗪-1,1-二氧化物衍生物的合成方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US130278A (en) * | 1872-08-06 | Improvement in pipe-tongs | ||
| US144274A (en) * | 1873-11-04 | Improvement in self-closing telegraph-keys | ||
| US151555A (en) * | 1874-06-02 | Improvement in street-railway switches | ||
| US151558A (en) * | 1874-06-02 | Improvement in the modes of machine-sewing | ||
| US156061A (en) * | 1874-10-20 | Improvement in boot and shoe nails | ||
| US129672A (en) * | 1872-07-23 | Improvement in heating-stoves | ||
| US156069A (en) * | 1874-10-20 | Improvement in lithographic printing-presses | ||
| US4172A (en) * | 1845-09-02 | Coal-breaker | ||
| US193377A (en) * | 1877-07-24 | Improvement in bee-hives | ||
| US161000A (en) * | 1875-03-23 | Improvement in millstone-bushes | ||
| US3655679A (en) * | 1969-06-25 | 1972-04-11 | Merck & Co Inc | Certain aryl pyridine carboxylic acid derivatives |
| US5521181A (en) * | 1995-01-27 | 1996-05-28 | Abbott Laboratories | Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists |
| US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
| CA2263886A1 (en) * | 1996-12-09 | 1998-06-18 | Warner-Lambert Company | Method for treating and preventing heart failure and ventricular dilatation |
| BR0207865A (pt) * | 2001-02-14 | 2004-03-23 | Warner Lambert Co | Benzotiadiazinas inibidores de metaloproteinases de matriz |
-
2002
- 2002-02-08 PA PA20028539301A patent/PA8539301A1/es unknown
- 2002-02-13 BR BR0207864-3A patent/BR0207864A/pt not_active IP Right Cessation
- 2002-02-13 CA CA002437643A patent/CA2437643A1/en not_active Abandoned
- 2002-02-13 EP EP02710275A patent/EP1361873A4/en not_active Withdrawn
- 2002-02-13 WO PCT/IB2002/000447 patent/WO2002064080A2/en not_active Ceased
- 2002-02-13 PY PY200200202788A patent/PY0202788A/es unknown
- 2002-02-13 AU AU2002228302A patent/AU2002228302A1/en not_active Abandoned
- 2002-02-13 SV SV2002000874A patent/SV2002000874A/es not_active Application Discontinuation
- 2002-02-13 AR ARP020100472A patent/AR033859A1/es not_active Application Discontinuation
- 2002-02-13 HN HN2002000037A patent/HN2002000037A/es unknown
- 2002-02-13 MX MXPA03007250A patent/MXPA03007250A/es unknown
- 2002-02-13 JP JP2002563877A patent/JP2004529874A/ja not_active Abandoned
- 2002-02-13 PE PE2002000116A patent/PE20020873A1/es not_active Application Discontinuation
- 2002-02-13 UY UY27174A patent/UY27174A1/es not_active Application Discontinuation
- 2002-02-13 US US10/075,069 patent/US20030078276A1/en not_active Abandoned
-
2004
- 2004-04-29 US US10/835,619 patent/US20050004126A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004529874A5 (https=) | ||
| TW309512B (https=) | ||
| JP5468007B2 (ja) | 新規なプロスタグランジンｉ２誘導体 | |
| JP2008505117A5 (https=) | ||
| JP2005532287A5 (https=) | ||
| CY1108996T1 (el) | Παραγωγα ινδολ-3-καρβονυλο-σπειρο-πιπεριδινης ως ανταγωνιστες του v1a υποδοχεα | |
| EP1489077A4 (en) | 2- FURANCARA ACID HYDRATES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | |
| NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister | |
| EA200500096A1 (ru) | Гетеробиарильные производные в качестве ингибиторов матриксных металлопротеиназ | |
| ATE386014T1 (de) | Meldoniumsalze, verfahren zu deren herstellung und auf ihnen basierende pharmazeutische zusammensetzung | |
| JP2010501478A5 (https=) | ||
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| RU2007108863A (ru) | Производные пиразола для лечения состояний, опосредованных активацией рецептора аденозина а2в или а3 | |
| JP2020529988A5 (https=) | ||
| JP2005514457A5 (https=) | ||
| JP2002543114A5 (https=) | ||
| Liu et al. | Design, synthesis, and biological evaluation of new 1, 2, 3-triazolo-2′-deoxy-2′-fluoro-4′-azido nucleoside derivatives as potent anti-HBV agents | |
| CN109053854A (zh) | 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用 | |
| JPS6360755B2 (https=) | ||
| Wucherer-Plietker et al. | Discovery of novel 7-azaindoles as PDK1 inhibitors | |
| JP2008069182A5 (https=) | ||
| WO2006043655A1 (ja) | 吸入用医薬組成物 | |
| JP2005511594A5 (https=) | ||
| Hartung et al. | Optimization of allosteric MEK inhibitors. Part 1: venturing into underexplored SAR territories | |
| Zheng et al. | Pyridopyrimidine analogues as novel adenosine kinase inhibitors |